WO2011056655A3 - Use of cell lines to determine levels of efficacy of pharmaceutical formulations - Google Patents

Use of cell lines to determine levels of efficacy of pharmaceutical formulations Download PDF

Info

Publication number
WO2011056655A3
WO2011056655A3 PCT/US2010/054296 US2010054296W WO2011056655A3 WO 2011056655 A3 WO2011056655 A3 WO 2011056655A3 US 2010054296 W US2010054296 W US 2010054296W WO 2011056655 A3 WO2011056655 A3 WO 2011056655A3
Authority
WO
WIPO (PCT)
Prior art keywords
efficacy
cell lines
pharmaceutical formulations
determine levels
assays
Prior art date
Application number
PCT/US2010/054296
Other languages
French (fr)
Other versions
WO2011056655A2 (en
Inventor
Vanja Margareta King
Original Assignee
Warsaw Orthopedic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warsaw Orthopedic, Inc. filed Critical Warsaw Orthopedic, Inc.
Publication of WO2011056655A2 publication Critical patent/WO2011056655A2/en
Publication of WO2011056655A3 publication Critical patent/WO2011056655A3/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486Analgesics, e.g. opiates, aspirine

Abstract

The present invention provides methods and assays for determining the efficacy of pharmaceutical compositions. Through the use of cell lines to measure efficacy of a formulation, one can better measure characteristics such as half life, release rate and release profile of a product that may be informative to the FDA. These methods and assays may, for example, be of use when measuring the effect of anti-inflammatory agents on cytokine production that is being considered for local administration.
PCT/US2010/054296 2009-10-28 2010-10-27 Use of cell lines to determine levels of efficacy of pharmaceutical formulations WO2011056655A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/607,199 2009-10-28
US12/607,199 US20110097748A1 (en) 2009-10-28 2009-10-28 Use of cell lines to determine levels of efficacy of pharmaceutical formulations

Publications (2)

Publication Number Publication Date
WO2011056655A2 WO2011056655A2 (en) 2011-05-12
WO2011056655A3 true WO2011056655A3 (en) 2011-07-28

Family

ID=43898751

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/054296 WO2011056655A2 (en) 2009-10-28 2010-10-27 Use of cell lines to determine levels of efficacy of pharmaceutical formulations

Country Status (2)

Country Link
US (1) US20110097748A1 (en)
WO (1) WO2011056655A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040086246A (en) * 2001-12-21 2004-10-08 이스턴 버지니아 메디컬 스쿨 Method for analyzing effects of medical agents
US20070243599A1 (en) * 2005-12-30 2007-10-18 Centocor Research & Development, Inc. Method for determining the phenotype of cells
US7575868B2 (en) * 1996-07-12 2009-08-18 Precision Therapeutics, Inc. Methods for assessing efficacy of chemotherapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224956D0 (en) * 1992-11-28 1993-01-20 Euro Dpc Ltd Improvements relating to allergen testing & apparatus
US5728541A (en) * 1996-07-12 1998-03-17 Precision Therapeutics, Inc. Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
US7815944B2 (en) * 2001-06-20 2010-10-19 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment of prevention of gastric toxicity
WO2005026348A1 (en) * 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Screening method
US9132085B2 (en) * 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7575868B2 (en) * 1996-07-12 2009-08-18 Precision Therapeutics, Inc. Methods for assessing efficacy of chemotherapeutic agents
KR20040086246A (en) * 2001-12-21 2004-10-08 이스턴 버지니아 메디컬 스쿨 Method for analyzing effects of medical agents
US20070243599A1 (en) * 2005-12-30 2007-10-18 Centocor Research & Development, Inc. Method for determining the phenotype of cells

Also Published As

Publication number Publication date
WO2011056655A2 (en) 2011-05-12
US20110097748A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
AU2013293116A8 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
IL224288A (en) Derivatives of substituted pyrazolamide, pharmaceutical compositions comprising the same and uses thereof
EP2251038A4 (en) Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both
WO2012021715A3 (en) Stable formulations of linaclotide
WO2010123919A3 (en) Piperidine inhibitors of janus kinase 3
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
MX354102B (en) Benzimidazole-proline derivatives.
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
WO2009091576A3 (en) Parenteral formulations of dopamine agonists
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
WO2011131943A3 (en) Pharmaceutical compositions
WO2011106248A3 (en) Trimethoxyphenyl inhibitors of tyrosine kinase
WO2010147830A3 (en) Aminothiazole modulators of beta-3-adrenoreceptor
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
WO2011134962A3 (en) Orally disintegrating tablet containing acarbose
UA110979C2 (en) Liquid pharmaceutical formulation comprising nitisinone
MX2009007764A (en) Extended release formulation of nevirapine.
WO2010033167A3 (en) Anti-thrombin aptamer formulations and methods for use
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
WO2013006308A3 (en) Dihydropyrazoles, pharmaceutical compositions thereof and their use for the treatment of fertility disorders
WO2011150457A3 (en) Haematopoietic-prostaglandin d2 synthase inhibitors
WO2010077730A3 (en) Indanone inhibitors of acetylcholinesterase
WO2012003495A3 (en) Automated equipment for hydration, mixing and delivery of alginate to a pellet forming device
EP2983684B8 (en) Essential oil and aloe for treatment and prophylaxis of inflammations caused by demodex, especially marginal blepharitis, a pharmaceutical composition containing essential oil and/or aloe and the use of essential oil and aloe and their compositions for the production of a preparation used in treatment and prophylaxis of the mentioned inflammations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10828892

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10828892

Country of ref document: EP

Kind code of ref document: A2